$Arcturus Therapeutics (ARCT.US)$
Arcturus宣佈自我放大 COVID-19 mRNA 生物-疫苗候選ARCt-154在第3期研究中達到主要效力端點。
https://finance.yahoo.com/news/arcturus-announces-self-amplifying-covid-113000171.html
Arcturus宣佈自我放大 COVID-19 mRNA 生物-疫苗候選ARCt-154在第3期研究中達到主要效力端點。
https://finance.yahoo.com/news/arcturus-announces-self-amplifying-covid-113000171.html
已翻譯
1
$強生 (JNJ.US)$
強生支持的登革熱複合物表現出對抗該病毒及所有已知變異株的潛力,包括在老鼠身上。
https://www.fiercebiotech.com/research/dengue-pill-backed-by-j-j-shows-potency-against-virus-and-all-known-variants-mice
強生支持的登革熱複合物表現出對抗該病毒及所有已知變異株的潛力,包括在老鼠身上。
https://www.fiercebiotech.com/research/dengue-pill-backed-by-j-j-shows-potency-against-virus-and-all-known-variants-mice
已翻譯
$Arcturus Therapeutics (ARCT.US)$Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
https://finance.yahoo.com/news/arcturus-announces-approval-clinical-trial-130000038.html
https://finance.yahoo.com/news/arcturus-announces-approval-clinical-trial-130000038.html
1
3
$Vir Biotechnology (VIR.US)$sotrovimab取得了一些初步積極的結果。
"COMEt-ICE試驗中所有1,057名患者的主要有效性分析顯示,在Day 29與安慰劑相比,因各種原因導致住院超過24小時或死亡的風險減少了79%(調整後相對風險降低)(p<0.001),達到了試驗的主要終點。"
https://www.globenewswire.com/news-release/2021/06/21/2250117/0/en/GSk-and-Vir-Biotechnology-Announce-Continuing-Progress-of-the-COMEt-Clinical-Development-Program-for-Sotrovimab.html
https://www.reuters.com/article/health-coronavirus-gsk-usa/study-confirms-gsk-vir-antibody-drug-reduces-hospitalization-death-in-covid-19-patients-idUSL3N2O32Q9...
"COMEt-ICE試驗中所有1,057名患者的主要有效性分析顯示,在Day 29與安慰劑相比,因各種原因導致住院超過24小時或死亡的風險減少了79%(調整後相對風險降低)(p<0.001),達到了試驗的主要終點。"
https://www.globenewswire.com/news-release/2021/06/21/2250117/0/en/GSk-and-Vir-Biotechnology-Announce-Continuing-Progress-of-the-COMEt-Clinical-Development-Program-for-Sotrovimab.html
https://www.reuters.com/article/health-coronavirus-gsk-usa/study-confirms-gsk-vir-antibody-drug-reduces-hospitalization-death-in-covid-19-patients-idUSL3N2O32Q9...
已翻譯
2
$Arcturus Therapeutics (ARCT.US)$
02 June 2021
Primordial Genetics Grants Arcturus Therapeutics Exclusive License of an RNA Polymerase for Human and Animal Therapeutics
https://www.prnewswire.com/news-releases/primordial-genetics-grants-arcturus-therapeutics-exclusive-license-of-an-rna-polymerase-for-human-and-animal-therapeutics-301303621.html
02 June 2021
Primordial Genetics Grants Arcturus Therapeutics Exclusive License of an RNA Polymerase for Human and Animal Therapeutics
https://www.prnewswire.com/news-releases/primordial-genetics-grants-arcturus-therapeutics-exclusive-license-of-an-rna-polymerase-for-human-and-animal-therapeutics-301303621.html
$富途控股 (FUTU.US)$
The companies, FUTU AND TIGR, disclosed during earnings calls last month they are applying for licenses in Singapore and the U.S. that would allow local customers to trade digital currencies.
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
The companies, FUTU AND TIGR, disclosed during earnings calls last month they are applying for licenses in Singapore and the U.S. that would allow local customers to trade digital currencies.
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
$向上融科 (TIGR.US)$
這些公司在上個月收益通話中披露,他們正在新加坡和美國申請許可證,允許當地客戶交易數字貨幣。
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
這些公司在上個月收益通話中披露,他們正在新加坡和美國申請許可證,允許當地客戶交易數字貨幣。
https://www.cnbc.com/2021/06/01/chinas-robinhood-rivals-pile-into-the-crypto-craze.html?recirc=taboolainternal
已翻譯